Dr. Reddy's Laboratories Ltd (RDY)
RDY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/0001575872-26-000381-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-03-31. Converted from INR at 94.2431 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | RDY on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | India |
| IPO year | Not reported by the screener |
| SEC CIK | 0001135951 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | India |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.6B |
| Net income | $454.7M |
| Operating income | $536.4M |
| Net margin | 12.8% |
| Operating margin | 15.0% |
| Revenue growth | -6.5% |
| Cash | $163.1M |
| Total assets | $6.1B |
| P/E (computed) | 27.0× |
| P/S (computed) | 3.4× |
Reported in INR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-05-29 |
| Cash and burn | $163.1M cash; operating cash flow $150.6M a quarter. | Report 2026-03-31 |
| Shares outstanding | 834,656,970 (2026-03-31); 834,455,365 a year earlier; 166,527,876 three years earlier. 3y figure adjusted for splits (5-for-1 overall); the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures. | Cover page 2026-03-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young Associates LLP, Hyderabad, India | PCAOB Form AP 2026-06-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-03-31 | $3.6B | $454.7M | $602.2M | $163.1M | $193.2M | $3.6B | 20-F 2026-05-29 |
| FY 2025 2025-03-31 | $3.8B | $663.0M | $545.0M | $172.0M | $537.0M | $3.8B | 20-F 2025-06-06 |
| FY 2024 2024-03-31 | $3.4B | $668.0M | $545.0M | $85.0M | $225.0M | $3.4B | 20-F 2024-06-12 |
| FY 2023 2023-03-31 | $3.0B | $548.0M | $716.0M | $70.0M | $106.0M | $3.0B | 20-F 2023-06-13 |
| FY 2022 2022-03-31 | $2.8B | $311.0M | $370.0M | $196.0M | $433.0M | $2.8B | 20-F 2022-06-27 |
| FY 2021 2021-03-31 | $2.6B | $236.0M | $488.0M | $203.0M | $402.0M | $2.6B | 20-F 2021-06-30 |
| FY 2020 2020-03-31 | $2.3B | $259.0M | $396.0M | $27.0M | $235.0M | $2.3B | 20-F 2020-06-15 |
| FY 2019 2019-03-31 | $2.2B | $272.0M | $415.0M | $32.0M | $493.0M | $2.2B | 20-F 2019-06-03 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report FORM 20-F | 20-F | 2026-05-29 |
| Latest quarterly / interim FORM 6K | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.1% |
| 1 month | +15.4% |
| 3 months | +18.7% |
| Year to date | +5.0% |
| 1 year | +6.3% |
| From 52-week high | -4.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELAN | Elanco Animal Health Incorporated | $26.41 | -1.38% | $13.2B |
| BMRN | BioMarin Pharmaceutical Inc. | $57.99 | +1.33% | $11.2B |
| BBIO | BridgeBio Pharma Inc. | $77.36 | -1.20% | $15.1B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $239.77 | -0.74% | $15.4B |
| TGTX | TG Therapeutics Inc. | $62.76 | -2.71% | $9.5B |
| SMMT | Summit Therapeutics Inc. Common Stock | $11.82 | -16.47% | $9.5B |
| SYRE | Spyre Therapeutics Inc. | $99.37 | -4.45% | $9.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier